Suivi thérapeutique pharmacologique du topiramate

2007, Résumé des Caractéristiques du Produit du topiramate Mulleners, 2008, Anticonvulsants in migraine prophylaxis: a Cochrane review, Cephalalgia, 28, 585, 10.1111/j.1468-2982.2008.01571.x Dib, 2004, Focus on topiramate in neuropathic pain, Curr Med Res Opin, 20, 1857, 10.1185/030079904X11358 Vasudev, 2006, Topiramate for acute affective episodes in bipolar disorder, Cochrane Database Syst Rev, CD003384 Cates, 2008, Efficacy of add-on topiramate therapy in psychiatric patients with weight gain, Ann Pharmacother, 42, 505, 10.1345/aph.1K520 Supuran, 2008, Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity, Expert Opin Emerg Drugs, 13, 383, 10.1517/14728214.13.2.383 Ben-Menachem, 1997, Topiramate: current status and therapeutic potential, Expert Opin Investig Drugs, 6, 1085, 10.1517/13543784.6.8.1085 Glauser, 1999, Topiramate, Epilepsia, 40, S71, 10.1111/j.1528-1157.1999.tb00922.x Langtry, 1997, Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy, Drugs, 54, 752, 10.2165/00003495-199754050-00009 Lyseng-Williamson, 2007, Topiramate: a review of its use in the treatment of epilepsy, Drugs, 67, 2231, 10.2165/00003495-200767150-00008 Perucca, 1997, A pharmacological and clinical review on topiramate, a new antiepileptic drug, Pharmacol Res, 35, 241, 10.1006/phrs.1997.0124 Privitera, 1997, Topiramate: a new antiepileptic drug, Ann Pharmacother, 31, 1164, 10.1177/106002809703101010 Rosenfeld, 1997, Topiramate: a review of preclinical, pharmacokinetic, and clinical data, Clin Ther, 19, 1294, 10.1016/S0149-2918(97)80006-9 Shank, 2000, An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action, Epilepsia, 41, S3, 10.1111/j.1528-1157.2000.tb02163.x Shank, 2008, Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate, CNS Neurosci Ther, 14, 120, 10.1111/j.1527-3458.2008.00041.x Adin, 2004, Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications, Ther Drug Monit, 26, 251, 10.1097/00007691-200406000-00005 May, 2002, Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication, Ther Drug Monit, 24, 366, 10.1097/00007691-200206000-00007 Bourgeois, 1999, Pharmacokinetics and metabolism of topiramate, Drugs Today (Barc), 35, 43, 10.1358/dot.1999.35.1.522947 Perucca, 1996, Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs, Epilepsia, 37, S8, 10.1111/j.1528-1157.1996.tb06032.x Doose, 1996, Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug, J Clin Pharmacol, 36, 884, 10.1002/j.1552-4604.1996.tb04754.x Shank, 2005, Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase, Epilepsy Res, 63, 103, 10.1016/j.eplepsyres.2005.01.001 Christensen, 2001, Plasma concentration of topiramate correlates with cerebrospinal fluid concentration, Ther Drug Monit, 23, 529, 10.1097/00007691-200110000-00006 Reife, 1995, Topiramate PK/PD analysis, Epilepsia, 36, 152 Penovich, 1997, Clinical experience with topiramate: correlation of serum levels with efficacy and adverse events, Epilepsia, 38, 181 Twyman, 1999, Plasma topiramate (TPM) concentration vs. therapeutic response during monotherapy, Epilepsia, 40, 111 Mahmood, 1998, Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsant drugs? Experience with four anticonvulsant drugs, Clin Pharmacol Ther, 64, 547, 10.1016/S0009-9236(98)90138-2 Gilliam, 2003, A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy, Neurology, 60, 196, 10.1212/01.WNL.0000048200.12663.BC Ferrari, 2003, Influence of dosage, age, and comedication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response, Ther Drug Monit, 25, 700, 10.1097/00007691-200312000-00008 Zanotta, 2006, Clinical experience with topiramate dosing and serum levels in patients with epilepsy, Seizure, 15, 86, 10.1016/j.seizure.2005.11.003 Christensen, 2003, Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy, Neurology, 61, 1210, 10.1212/01.WNL.0000091867.09720.6B Froscher, 2005, Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy, Epileptic Disord, 7, 237 Contin, 2002, Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs, Ther Drug Monit, 24, 332, 10.1097/00007691-200206000-00002 Battino, 2005, Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data, Clin Pharmacokinet, 44, 407, 10.2165/00003088-200544040-00005 Dahlin, 2004, Age and antiepileptic drugs influence topiramate plasma levels in children, Pediatr Neurol, 31, 248, 10.1016/j.pediatrneurol.2004.04.005 Glauser, 1999, Topiramate pharmacokinetics in infants, Epilepsia, 40, 788, 10.1111/j.1528-1157.1999.tb00780.x Mikaeloff, 2004, Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years, Epilepsia, 45, 1448, 10.1111/j.0013-9580.2004.65503.x Rosenfeld, 1999, A study of topiramate pharma-cokinetics and tolerability in children with epilepsy, Pediatr Neurol, 20, 339, 10.1016/S0887-8994(99)00011-9 Gisclon, 1993, The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function, Pharm Res, 10, S397 Westin, 2009, Serum concentration/dose ratio of topiramate during pregnancy, Epilepsia, 50, 480, 10.1111/j.1528-1167.2008.01776.x Sachdeo, 2002, Topiramate and phenytoin phar-macokinetics during repetitive monotherapy and combination therapy to epileptic patients, Epilepsia, 43, 691, 10.1046/j.1528-1157.2002.41701.x Britzi, 2005, Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine, Epilepsia, 46, 378, 10.1111/j.0013-9580.2005.55204.x Mimrod, 2005, A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy, Epilepsia, 46, 1046, 10.1111/j.1528-1167.2005.06805.x Sachdeo, 1996, Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy, Epilepsia, 37, 774, 10.1111/j.1528-1157.1996.tb00651.x Rosenfeld, 1997, Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy, Epilepsia, 38, 324, 10.1111/j.1528-1157.1997.tb01124.x Doose, 2003, Topiramate and lamotrigine phar-macokinetics during repetitive monotherapy and combination therapy in epilepsy patients, Epilepsia, 44, 917, 10.1046/j.1528-1157.2003.64402.x Rosenfeld, 1997, Effect of topiramate on the phar-macokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy, Epilepsia, 38, 317, 10.1111/j.1528-1157.1997.tb01123.x Marriott, 2009, Posaconazole-induced topiramate toxicity, Ann Intern Med, 151, 143, 10.7326/0003-4819-151-2-200907210-00018 Berry, 2000, Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay, Ther Drug Monit, 22, 460, 10.1097/00007691-200008000-00016 Bahrami, 2004, Sensitive analytical method for topiramate in human serum by HPLC with pre-column fluorescent derivatization and its application in human pharmacokinetic studies, J Chromatogr B Analyt Technol Biomed Life Sci, 813, 175, 10.1016/j.jchromb.2004.09.054 Britzi, 2003, Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay, Ther Drug Monit, 25, 314, 10.1097/00007691-200306000-00012 Chen, 1999, Rapid approach to the quantitative determination of top iramate (2, 3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate) in human plasma by liquid-liquid extraction and flow-injection negative-ion electrospray mass spectrometry, Rapid Commun Mass Spectrom, 13, 1980, 10.1002/(SICI)1097-0231(19991030)13:20<1980::AID-RCM741>3.0.CO;2-C Christensen, 2002, Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: validation and comparison with fluorescence-polarization immunoassay, Ther Drug Monit, 24, 658, 10.1097/00007691-200210000-00013 Contin, 2001, Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma, J Chromatogr B Biomed Sci Appl, 761, 133, 10.1016/S0378-4347(01)00302-4 Cooper, 1991, A capillary GC assay with NPD detection for the quantification of topiramate in human plasma, Pharm Res, 10, 19 Holland, 1988, Automated capillary gas chromatographic as say using flame ionization detection for the determination of topiramate in plasma, J Chromatogr, 433, 276, 10.1016/S0378-4347(00)80608-8 Riffitts, 1999, A capillary gas chromatographic as say with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood, J Pharm Biomed Anal, 19, 363, 10.1016/S0731-7085(98)00137-X Tang, 2000, An improved gas chromatography as say for topiramate monitoring in pediatric patients, Ther Drug Monit, 22, 195, 10.1097/00007691-200004000-00010 Wolf, 2000, Rapid gas chromatographic procedure for the determination of topiramate in serum, J Anal Toxicol, 24, 661, 10.1093/jat/24.7.661 Johannessen, 2003, Therapeutic drug monitoring of the newer antiepileptic drugs, Ther Drug Monit, 25, 347, 10.1097/00007691-200306000-00016 Johannessen, 2006, Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?, Clin Pharmacokinet, 45, 1061, 10.2165/00003088-200645110-00002 Patsalos, 2008, Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies, Epilepsia, 49, 1239, 10.1111/j.1528-1167.2008.01561.x Perucca, 2000, Is there a role for therapeutic drug monitoring of new anticonvul sants?, Clin Pharmacokinet, 38, 191, 10.2165/00003088-200038030-00001 Perucca, 1996, The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine, Clin Pharmacokinet, 31, 29, 10.2165/00003088-199631010-00003 Tomson, 2000, Therapeutic monitoring of the new antiepileptic drugs, Eur J Clin Pharmacol, 55, 697, 10.1007/s002280050001